Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1144412 | 1.00 | ALDH1A1 (0.51) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 | |
| SCHEMBL167043 | 1.00 | ALDH1A1 (0.51) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 | |
| Hydrochloric Acid SCHEMBL6373800 | 0.98 | ALDH1A1 (0.50) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 | |
| Hydrochloric Acid SCHEMBL2203097 | 0.98 | ALDH1A1 (0.50) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 | |
| Hydrochloric Acid SCHEMBL476789 | 0.98 | ALDH1A1 (0.50) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 | |
| SCHEMBL4591411 | 0.93 | KCNA5 (0.49) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 | |
| SCHEMBL1144253 | 0.93 | KCNA5 (0.49) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 | |
| Tartaric Acid SCHEMBL29904324 | 0.92 | ALDH1A1 (0.46) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 | |
| SCHEMBL2299744 | 0.90 | PTGS2 (0.46) | ALDH1A1KCNA5KMT2ACYP3A4 | |
| SCHEMBL27575989 | 0.88 | KMT2A (0.44) | ALDH1A1KCNA5KMT2ATSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106883133-A | A kind of preparation method of dapoxetine hydrochloride | 南京斯贝源医药科技有限公司 | 2017-06-23 | — | — | CN | claimed |
| EP-2088152-B1 | N'-{N-[3-OXO-LUPEN-28-OYL]-9-AMINONONANOYL}-3-AMINO-3-PHENYLPROPEONIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, A METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A MEDICINAL AGENT | INST NEFTEKHIMII I KATALIZA ROSSIISKOI AKADEMII NAUK (RU) | 2012-02-01 | — | — | EP | claimed |
| US-20100087539-A1 | N'--3-AMINO-3-PHENYLPROPEONIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, A METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A MEDICINAL AGENT | INSTITUT NEFTEKHIMII I KATALIZA ROSSIISKOI AKADEMII NAUK (RU) | 2010-04-08 | — | — | US | claimed |
| EP-2088152-A1 | N'-{N-[3-OXO-LUPEN-28-OYL]-9-AMINONONANOYL}-3-AMINO-3-PHENYLPROPEONIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, A METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A MEDICINAL AGENT | Institut Neftekhimii I Kataliza Rossiiskoi Akademii Nauk (RU) | 2009-08-12 | — | — | EP | claimed |
| CN-120192280-A | Synthesis of amino acid derivatives containing 1,3, 4-oxadiazole thioether and application of amino acid derivatives in resisting plant bacterial diseases | 贵州大学 | 2025-06-24 | — | — | CN | disclosed |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| CN-113880721-B | Synthesis method of dapoxetine | 湖南九典制药股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4313051-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | Virginia Commonwealth University (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230312466-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-10-05 | — | — | US | disclosed |
| WO-2022212471-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
| EP-0355819-B1 | Substituted aryl ureas as high potency sweeteners | NUTRASWEET CO (US) | 1994-01-05 | — | — | EP | disclosed |
| US-5136050-A | Process for resolving amino acids using substituted lactones | ROUSSEL UCLAF (FR) | 1992-08-04 | — | — | US | disclosed |
| CN-1043125-A | Be used as the aryl urea of the replacement of high-potency sweetener | NUTRASWEET CO (US) | 1990-06-20 | — | — | CN | disclosed |
| WO-1990002112-A1 | SUBSTITUTED ARYL UREAS AS HIGH POTENCY SWEETENERS | THE NUTRASWEET COMPANY (US) | 1990-03-08 | — | — | WO | disclosed |
| EP-0355819-A1 | Substituted aryl ureas as high potency sweeteners | THE NUTRASWEET COMPANY (a Delaware corporation) (US) | 1990-02-28 | — | — | EP | disclosed |
| US-4513139-A | Substituted lactones of amino acids | ROUSSEL UCLAF (FR) | 1985-04-23 | — | — | US | disclosed |
| US-4350637-A | STEREOISOMERS, RESOLUTION | ROUSSEL UCLAF (FR) | 1982-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312466-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | ALDH1A1 516/4885KCNA5 2461/4885KMT2A 4450/4885 |
| US-20100087539-A1 | N'--3-AMINO-3-PHENYLPROPEONIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, A METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A MEDICINAL AGENT | GART, DNPEP, IL4I1 | ALDH1A1 487/4885KCNA5 4016/4885KMT2A 4370/4885 |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | OPRM1, OPRK1, CCR5 | ALDH1A1 3596/4885KCNA5 2689/4885KMT2A 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.